Hematopoietic Stem Cell Transplantation Market Forecast: Future Prospects

 

Hematopoietic stem cell transplantation (HSCT) involves transplantation of hematopoietic stem cells to treat hematological malignancies and genetic disorders of the blood or immune system in conjunction with high-dose chemotherapy. HSCT allows for replacement of defective or destroyed bone marrow with healthy bone marrow stem cells. The increasing prevalence of hematological malignancies such as leukemia, lymphoma and multiple myeloma leading to increased demand for HSCT procedures globally. HSCT procedures help in treating these conditions by replacing a patient's bone marrow with healthy bone marrow stem cells from a donor. The Global Hematopoietic stem cell transplantation (HSCT) Market is estimated to be valued at US$ 2.88 Bn in 2024 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the Hematopoietic stem cell transplantation (HSCT) are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, FUJIFILM Holdings Corporation. These key players are actively focusing on new product development and launch, collaborations and acquisition strategies to strengthen their presence in the HSCT market.

There is high growth opportunity for players in the HSCT market owing to increasing adoption of haploidentical HSCT, expansion of clinical applications of HSCT and increase in number of clinical trials evaluating efficacy of new HSCT protocols. North America represents the largest market for HSCT currently however Asia Pacific region presents high growth opportunity owing to increasing healthcare investments and expenditure in countries like India and China. Key players are expanding their presence in Asia Pacific region to tap this growth opportunity.

Market Drivers

One of the key drivers augmenting the growth of HSCT market is increasing prevalence of hematological malignancies globally. According to the World Health Organization (WHO), around 700,000 new cases of leukemia are diagnosed each year worldwide. Moreover, around 400,000 new cases of non-Hodgkin lymphoma are reported annually. Rising cases of these blood cancers in turn increases the demand for HSCT as it is one of the commonly used treatment protocols for such conditions.

Market Restrain

High cost associated with HSCT procedures is a major challenge restraining the growth of HSCT market. HSCT involves complex procedures requiring specialized infrastructure and equipment. It also requires specialized training of medical professionals. Moreover, factors such as longer hospital stays and costs associated with managing post transplantation complications make HSCT an expensive treatment option. This high cost prevents many patients from opting for HSCT thereby restricting the market growth to some extent.
Segment Analysis
The autologous segment dominated the market in 2022 and is expected to continue its dominance during the forecast period. Autologous HSCT involves the transplantation of stem cells from the patient's own body. This eliminates the risk of complications such as graft-versus-host disease. Autologous transplants are preferred over allogeneic procedures for treating diseases such as lymphoma, multiple myeloma, and neuroblastoma.

Global Analysis
North America dominated the hematopoietic stem cell transplantation (HSCT) market in 2022 owing to advanced healthcare infrastructure and high adoption of stem cell therapy. Increase in blood cancer prevalence coupled with rising number of HSCT procedures performed is also driving market growth in the region. Asia Pacific is expected to witness the fastest growth during the forecast period due to rising healthcare expenditure, increasing cancer incidence, and growing awareness about HSCT therapy. Additionally, developing economies are attracting stem cell research funding and global players are expanding presence in Asia Pacific to tap high growth opportunities.